In myelodysplastic syndromes (MDS), ineffective hematopoiesis poses danger for worsening anemia, progressive disease, and reduced survival.^1-4

Significant unmet need remains for patients with lower-risk MDS and worsening anemia. Those who are ineligible for or have tried other treatment options experience the highest degree of unmet needs.^2,5-8